Key facts
- Eric Cantor, former US House Majority Leader, has been named president and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA).
- Cantor will begin his new role on November 9, succeeding Stephen J. Ubl.
- PhRMA highlighted Cantor's past support for the Medicare Part D prescription drug program, rare pediatric disease research funding, and the 21st Century Cures Act.
- Rob Davis, PhRMA board chair and CEO of Merck, stated Cantor possesses experience in business, policy, and politics.
Eric Cantor, a former US House Majority Leader, has been appointed as the next president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), a prominent US pharmaceutical lobby group. Cantor, who served in the House of Representatives from 2000 to 2014, will officially take over the role on November 9. He succeeds Stephen J. Ubl, who has led PhRMA since 2015. PhRMA highlighted Cantor's past support for the Medicare Part D prescription drug program, funding for rare pediatric disease research, and the 21st Century Cures Act during his time in Congress. Rob Davis, PhRMA board chair and CEO of Merck, noted Cantor's experience in business, policy, and politics. Ubl will remain with the organization as a strategic adviser until mid-January 2027 to facilitate the transition.
